Finn
CORT Biotechnology · Commercial biotech · Cortisol modulators · Oncology launch · Thesis updated August 5, 2026

Diversification begins while generic risks solidify

01 Running thesis

Diversification is finally real

Corcept used to be almost entirely dependent on Korlym. That made the company simple to understand but fragile. In March 2026, the FDA approved Lifyorli for platinum-resistant ovarian cancer, and Corcept began selling it in April. That turns Corcept from a Cushing's syndrome company into a commercial business with two distinct franchises.

The early Lifyorli launch looks promising. Management said prescriptions were written by over 200 physicians in the first month of launch. Lifyorli was also added to NCCN cancer treatment guidelines as a preferred regimen shortly after approval, which can help doctors and insurers adopt it faster.

The bull case is that Lifyorli ramps quickly, Korlym demand turns into reported revenue as pharmacy backlogs clear, and the FDA approves relacorilant for Cushing's syndrome on its December 17, 2026 target date. A positive FDA decision would secure the company's next-generation endocrine franchise.

The bear case remains serious. Korlym faces certain generic pressure after Corcept exhausted its Teva patent appeals in July 2026. SG&A spending jumped to support the new launches. If Lifyorli sales build slowly or the FDA rejects relacorilant again, the company could struggle to offset the eventual decline of its core business.

Jul 2026→The U.S. Court of Appeals denied Corcept's petition for a rehearing on the Teva patent litigation. The FDA also assigned a December 17, 2026 target date for the relacorilant Cushing's review.
Jun 2026▲Corcept resubmitted the relacorilant NDA for Cushing's syndrome after the FDA's December 2025 rejection. This gives the program a clearer path and likely shifts the next major readout to the FDA review cycle.
Apr 2026▲Management raised 2026 revenue guidance to $950 million to $1.05 billion. Early Lifyorli adoption was strong, with prescriptions from over 200 physicians in the first 36 days.
Apr 2026→Q1 2026 revenue rose to $164.9 million, but SG&A rose sharply to support commercialization. Korlym prescriptions hit records, while insurance and pharmacy backlogs delayed some revenue recognition.
Feb 2026▼The 2025 10-K captured two major hits: the FDA rejected relacorilant for Cushing's syndrome, and Corcept lost its final Teva patent appeal. The positive offset was strong ovarian cancer data for relacorilant.
Nov 2025→The thesis stayed centered on Korlym defense and relacorilant execution. Pharmacy capacity was improving, but the SG&A build for future launches raised execution risk.
02 Business model

Specialty drugs fund the pipeline

Corcept makes money by selling specialty medicines in the United States. Korlym and its authorized generic treat high blood sugar in adults with endogenous Cushing's syndrome. Lifyorli, which uses the same active drug as relacorilant, is sold with nab-paclitaxel for certain ovarian cancer patients.

The company relies on cash flow from the established Korlym franchise and the new Lifyorli launch to fund an R&D pipeline of selective cortisol modulators. Management expects full-year 2026 revenue between $950 million and $1.05 billion.

The model works best when specialty pharmacies, insurers, and doctors move patients through the system quickly. Corcept has been expanding its pharmacy network to clear prior authorization backlogs and capture strong underlying demand.

Costs are rising with the bigger ambition. Selling, general, and administrative expenses increased significantly in early 2026 to support commercialization of the hypercortisolism products and Lifyorli. That spending is sensible if both launches work, but painful if either one misses.

03 Product portfolio

Korlym pays, Lifyorli grows

Cash cow

Korlym

Korlym treats hyperglycemia in adult patients with endogenous Cushing's syndrome. It remains the main revenue base, but it faces generic pressure.

Steady

Authorized generic Korlym

Corcept launched an authorized generic in June 2024. It helps defend volume, but it also lowers average selling price.

Growth engine

Lifyorli

Lifyorli was approved in March 2026 for certain platinum-resistant ovarian cancer patients and launched in April 2026. It is the key new growth driver.

Option

Relacorilant for Cushing's syndrome

Corcept resubmitted the application in June 2026 after a previous rejection. The FDA set a target action date of December 17, 2026.

Option

Miricorilant for MASH

Miricorilant is being studied for MASH, a liver disease linked to fat buildup and inflammation. Enrollment in the Phase 2b MONARCH trial is complete.

Option

Dazucorilant for ALS

Dazucorilant is planned for a pivotal Phase 3 trial in ALS in 2026. This is a high-risk neurology program.

Option

Nenocorilant in oncology

Nenocorilant is being tested with nivolumab in the Phase 1b SYNERGY trial for solid tumors. It is part of Corcept's broader bet on cortisol modulation in cancer.

04 Business segments

One reported segment, two markets

Endocrinology100%modest
Oncology0%growing fast
Metabolic diseases0%flat
Neurology0%flat

Corcept operates as a single business segment. Lifyorli sales began in April 2026, meaning future reports will begin to reflect a mix of oncology and endocrinology revenue.

05 Risk factors

What can break the story

Korlym generic erosion

High impact · High odds

Corcept lost its final Teva patent appeal in July 2026 when the court denied a rehearing. That finalizes the loss of patent protection and solidifies the long-term threat of revenue and margin erosion from generic entrants.

We watchTrack Korlym volume, average price, and any new generic launch disclosures.

Slow Lifyorli ramp

High impact · Medium odds

Lifyorli started well with over 200 prescribers early in the launch. The next test is revenue. If payer access, patient starts, or gross-to-net discounts disappoint, Lifyorli may not offset Korlym pressure.

We watchWatch Q2 and Q3 2026 Lifyorli sales, prescriber growth, and gross-to-net commentary.

Cushing's regulatory setback

High impact · Medium odds

The FDA is reviewing the relacorilant resubmission for Cushing's syndrome with a December 17, 2026 target date. A second rejection would permanently impair the endocrine pipeline.

We watchWatch for FDA advisory committee announcements and the December action date.

Launch spending outruns revenue

Medium impact · Medium odds

Operating expenses are rising to support the Lifyorli and hypercortisolism launches. If sales do not ramp fast enough to cover these costs, profits and cash flow could stay under pressure.

We watchCompare quarterly revenue growth against SG&A and R&D spending.

Legal overhang

Medium impact · Medium odds

Corcept faces an antitrust lawsuit from Teva scheduled for a March 2027 trial. The company is also dealing with a securities class action. These cases can cost money, take management time, and hurt investor trust.

We watchWatch court filings, settlement talks, and any reserve or expense disclosure in filings.
06 Quick answers

In one breath

What does Corcept Therapeutics do?

Corcept develops and sells medicines that block or modulate cortisol, a hormone tied to stress and metabolism. Its main commercial products are Korlym for Cushing's syndrome and Lifyorli for ovarian cancer.

Why does Lifyorli matter so much for CORT stock?

Lifyorli is Corcept's first real revenue source outside Korlym. If it ramps well, Corcept becomes less dependent on a drug that faces generic competition.

What happened with relacorilant in Cushing's syndrome?

The FDA declined to approve it in December 2025 and asked for more evidence of efficacy. Corcept resubmitted the application in June 2026, and the FDA has set a target action date of December 17, 2026.

Is Corcept still dependent on Korlym?

Yes, for now. Most reported revenue still comes from hypercortisolism products, though Lifyorli sales began in April 2026 and are expected to grow.

Get started with Finn today